Vicapsys Inks Deal to Acquire FDA-Approved NitroMist, Eyes Puerto Rico Manufacturing Plant
VICP filed a M&A and Partnerships on elevated volume (9.6× avg).
Summary
Vicapsys has signed a definitive agreement to acquire NitroMist, an FDA-approved nitroglycerin spray for angina, for a $2.0 million convertible note. The product was voluntarily discontinued in 2022 but the NDA remains active, giving VICP a relaunch opportunity. The company is also in talks to buy a 120,000 sq ft manufacturing facility in Puerto Rico, which would enable in-house production. This follows yesterday's completion of the reverse merger with Stateline Distributors, creating a vertically integrated pharma platform targeting federal, tribal, and underserved markets. Leadership changes include Armando Rubio as CEO and the resignation of former CEO Federico Pier. Closing of the NitroMist deal is subject to FDA transfer acknowledgment and other conditions.
At the time of this announcement, VICP was trading at $0.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $16.2M. The 52-week trading range was $0.00 to $200.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.